These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16314737)

  • 21. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
    Bar J; Yerushalmi R; Shapira-Frummer R; Kutchuk I; Sulkes A; Gutman H; Catane R; Schachter J
    Oncol Rep; 2008 Dec; 20(6):1533-8. PubMed ID: 19020738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
    Mori T; O'Day SJ; Umetani N; Martinez SR; Kitago M; Koyanagi K; Kuo C; Takeshima TL; Milford R; Wang HJ; Vu VD; Nguyen SL; Hoon DS
    J Clin Oncol; 2005 Dec; 23(36):9351-8. PubMed ID: 16361635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006; 24(5):492-6. PubMed ID: 16939957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
    Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
    Keilholz U; Scheibenbogen C; Möhler T; Brossart P; Maclachlan D; Geueke AM; Jochim A; Hunstein W
    Melanoma Res; 1995 Aug; 5(4):283-7. PubMed ID: 7496166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer?
    Granato AM; Frassineti GL; Giovannini N; Ballardini M; Nanni O; Maltoni R; Amadori D; Volpi A
    Tumour Biol; 2006; 27(6):302-8. PubMed ID: 17028465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
    Richards JM; Gale D; Mehta N; Lestingi T
    J Clin Oncol; 1999 Feb; 17(2):651-7. PubMed ID: 10080611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
    J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
    J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
    Buzaid AC; Colome M; Bedikian A; Eton O; Legha SS; Papadopoulos N; Plager C; Ross M; Lee JE; Mansfield P; Rice J; Ring S; Lee JJ; Strom E; Benjamin R
    Melanoma Res; 1998 Dec; 8(6):549-56. PubMed ID: 9918417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab.
    Vihinen PP; Ramadan S; Vuoristo MS; Hernberg M; Tyynelä-Korhonen K; Skyttä T; Koskivuo I; Kellokumpu-Lehtinen PL; Syrjänen K; Pyrhönen S
    Melanoma Res; 2011 Oct; 21(5):431-7. PubMed ID: 21730877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
    Anderson CM; Buzaid AC; Sussman J; Lee JJ; Ali-Osman F; Braunschweiger PG; Plager C; Bedikian A; Papadopoulos N; Eton O; Legha SS; Grimm EA
    Melanoma Res; 1998 Apr; 8(2):149-55. PubMed ID: 9610868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo.
    Westphal JR; Van't Hullenaar R; Peek R; Willems RW; Crickard K; Crickard U; Askaa J; Clemmensen I; Ruiter DJ; De Waal RM
    Int J Cancer; 2000 Jun; 86(6):768-76. PubMed ID: 10842189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
    Rofstad EK; Halsør EF
    Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
    J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The prognostic role of clinical factors, VEGF, IL-8 and sTNF-R1 in cutaneous melanomas at locoregional stage].
    Ługowska I; Kowalska M; Zdzienicki M; Fuksiewicz M; Kamińska J; Szamotulska K; Rutkowski P
    Pol Merkur Lekarski; 2012 Jan; 32(187):22-7. PubMed ID: 22400175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.